

Bora Pharmaceuticals Reports Consolidated Revenue of NT\$1.53 Billion in March

保瑞公告 3 月自結合併營收新台幣 15 億 3 仟萬元

Taipei, Taiwan, April 9, 2026 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for March 2026 reached NT\$1.5 billion, a 15.22% rebound from February as competition landscape of DLS stabilized and a 6.28% increase from same month last year. In the meantime, though not reflected in consolidated revenues, Tanvex BioPharma rounded out a strong March, signaling broad-based recovery across the Group.

台北，台灣，2026 年 4 月 9 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 3 月自結合併營收為新台幣 15 億 3 仟萬元，較前月反彈 15.22%，主係胃食道逆流學名藥 DLS 重啟拉貨動能，且較去年同月增加 6.28%。此外，雖未併表，泰福月營收亦站上相對高檔，集團表現回溫。

Flagship NDA product VIGAFYDE[®] continues to deliver strong performance, and the Company is actively developing an onshoring production plan to support the long-term growth of this key asset. As the U.S. administration's requirements for domestic pharmaceutical supply chains come into sharper focus, particularly with respect to dosage form and therapeutic area, Bora believes its strategic investments over the past two years are well-positioned to deliver tangible returns.

值得注意的是，全球銷售的新旗艦產品 VIGAFYDE[®] 持續增長趨勢，保瑞積極規劃此關鍵產品回美製造，保瑞表示，當美國政府對回美製造的遊戲規則逐漸明朗，且劑型、治療領域需求越發明確，過去二年的布局將有更明確的回報。

Bora expects to receive full proceeds from its 5th domestic unsecured convertible bond next week. Combined with the 4th issuance, the two tranches represent gross proceeds of NT\$3 billion. With a healthy cash position, the Company continues to evaluate strategic investment opportunities, deepen brand development in support of pharma sales business expansion, and strengthen its CDMO capabilities.

保瑞預期於下周收足國內第五次無擔保可轉換債股款，第四暨第五次可轉換債共募得新台幣 30 億元，公司在手現金充足，持續評估策略投資方向，深化全球銷售的品牌發展以及 CDMO 技術競爭力。

About Bora:

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracdm.com>

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472.TW與BORAY.OTCQX）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracdm.com>

Investor/Media enquiries 新聞聯繫人：

Nadiya Chen, Investor Relations 投資人關係 陳荻雅

+886 2 790-1555 Ext. 9108

Email : Nadiya.Chen@bora-corp.com